目的 研究PET/CT用于肺小细胞 癌(NSCLC)术前检查对患者临床分期的影 响并分析其在患者预后中的应用价值。方 法 回顾性分析2011年6月至2013年6月我 院172例NSCLC手术治疗患者临床资料， 以术后病理检查结果为金标准，分析18FFDG PET/CT对肿瘤原发病灶、周围淋巴结 及远处转移检查结果的准确性，计算原发 病灶SUVmax并分析其对患者术后远期生存 情况的影响。结果 PET/CT检查对NSCLC 原发病灶术前T分期准确率为93.60%；对 N1、N2淋巴结及远处转移术前检测灵敏 度分别为88.16%、93.10%和92.59%，特 异度为79.17%、81.57%及81.37%，准确 率为83.14%、85.47%及83.14%，一致性 Kappa值为0.663、0.697及0.537；172 例NSCLC患者原发病灶SUVmax范围为3.2- 37.1，其中位数为12.4，以SUVmax=12.4为 临界值将患者分为两组，采用Log-rank 检验显示，SUVmax≤12.4患者DFS及OS均 高于SUVmax>12.4的患者，差异有统计学 意义(χ2 =3.864、4.889，P<0.05)。结论 PET/CT用于NSCLC术前检查可提高TNM分期 准确性，同时还能利用SUVmax值评估患者 预后情况，为临床选择合理治疗方案提供 重要依据。

Objective To study the effects of PET/CT on the clinical stages of patients with non-small-cell lung cancer (NSCLC) and to analyze its application value in the prognosis of patients. Methods The clinical data of 172 patients with NSCLC surgery from June 2011 to June 2013 were retrospectively analyzed retrospectively. The results of postoperative pathological examination were used as the gold standard to analyze the accuracies of 18F-FDG PET/CT in the detection of primary tumors, peripheral lymph nodes and distant metastasis, and the SUVmax of primary lesion was calculated and its effects on postoperative long-term survival were analyzed. Results The accuracy rate of PET/CT was 93.60% in the detection of preoperative T staging of NSCLC primary lesions. The sensitivities of preoperative detection of N1, N2 lymph nodes and distant metastasis were 88.16%, 93.10% and 92.59%, and the specificities were 79.17%, 81.57% and 81.37%, and the accuracy rates were 83.14%, 85.47% and 83.14%, and the consistency Kappa values were 0.663, 0.697 and 0.537.The SUVmax range was 3.2 to 37.1 among 172 patients with NSCLC with a median of 12.4. SUVmax=12.4 was used as the critical value to divide the patients into two groups. Log-rank test showed that the DFS and OS of patients with SUVmax≤12.4 were higher than those of patients with SUVmax >12.4 (χ2 =3.864, 4.889, P<0.05). Conclusion PET/CT for preoperative examination of NSCLC can improve the accuracy of TNM staging, and can also use SUVmax value to evaluate the prognosis of patients, and it provides an important basis for clinical selection of reasonable treatment regimens.